Literature DB >> 9871583

Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.

A K Ghosh1, J F Kincaid, W Cho, D E Walters, K Krishnan, K A Hussain, Y Koo, H Cho, C Rudall, L Holland, J Buthod.   

Abstract

Design and synthesis of a series of very potent nonpeptide HIV protease inhibitors are described. The inhibitors are derived from novel high affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9871583     DOI： 10.1016/s0960-894x(98)00098-5

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  53 in total

1.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

Review 2.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

3.  MULTICOMPONENT REACTIONS: SYNTHESIS OF SPIROCYCLIC TETRAHYDROPYRAN DERIVATIVES BY PRINS CYCLIZATION.

Authors:  Arun K Ghosh; Dongwoo Shin; Gary Schiltz
Journal:  Heterocycles       Date:  2002       Impact factor: 0.831

4.  Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.

Authors:  Kazuhiko Ide; Manabu Aoki; Masayuki Amano; Yasuhiro Koh; Ravikiran S Yedidi; Debananda Das; Sofiya Leschenko; Bruno Chapsal; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.

Authors:  Yasuhiro Koh; Manabu Aoki; Matthew L Danish; Hiromi Aoki-Ogata; Masayuki Amano; Debananda Das; Robert W Shafer; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

6.  Characterizing Protein-Ligand Binding Using Atomistic Simulation and Machine Learning: Application to Drug Resistance in HIV-1 Protease.

Authors:  Troy W Whitfield; Debra A Ragland; Konstantin B Zeldovich; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2020-01-16       Impact factor: 6.006

7.  Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464.

Authors:  Sami Osman; Brian J Albert; Yanping Wang; Miaosheng Li; Nancy L Czaicki; Kazunori Koide
Journal:  Chemistry       Date:  2010-11-19       Impact factor: 5.236

8.  Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Ravikiran S Yedidi; Rui Zhao; Hironori Hayashi; Kazuya Hasegawa; Tomofumi Nakamura; Cuthbert D Martyr; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

9.  Enantioselective Synthesis of Dioxatriquinane Structural Motifs for HIV-1 Protease Inhibitors Using a Cascade Radical Cyclization.

Authors:  Arun K Ghosh; Chun-Xiao Xu; Heather L Osswald
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

10.  A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Rui Zhao; Ravikiran S Yedidi; Debananda Das; Haydar Bulut; Nicole S Delino; Venkata Reddy Sheri; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.